Probucol: A Review of its Pharmacological Properties and Therapeutic Use in Patients with Hypercholesterolaemia
暂无分享,去创建一个
[1] W. Parsons. Effect of probucol in hyperlipidemic patients during two years of administration. , 1978, American heart journal.
[2] M. Verstraete. Antiplatelet Agents in Coronary Disease: Are They of Prophylactic Value? , 1978, Drugs.
[3] Y. Huang,et al. Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia. , 1977, Archives of internal medicine.
[4] G. Rosenhamer,et al. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. , 1977, Atherosclerosis.
[5] H. S. Sodhi,et al. Probucol: A new cholesterol‐lowering drug effective in patients with type II hyperlipoproteinemia , 1976, Clinical pharmacology and therapeutics.
[6] H. B. Brown,et al. The additive effect of probucol on diet in hyperlipidemia , 1974, Clinical pharmacology and therapeutics.
[7] R. S. Harris,et al. Long‐Term Oral Administration of Probucol [4, 4‘‐(Isopropylidenedithio) bis (2, 6‐di‐t‐Butylphenol)] (DH‐581) in the Management of Hypercholesterolemia * , 1974, Journal of the American Geriatrics Society.
[8] J. Lewis,et al. Sensitization to epinephrine-induced ventricular fibrillation produced by probucol in dogs. , 1973, Toxicology and applied pharmacology.
[9] J. Molello,et al. Toxicity of (4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol)), probucol, in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon. , 1973, Toxicology and applied pharmacology.
[10] C. H. Duncan,et al. The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterol. , 1973, Atherosclerosis.
[11] T. Miettinen. Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemia. , 1972, Atherosclerosis.
[12] M. Dacquisto,et al. Biphenabid (Probucol): a new hypocholesterolemic agent. , 1971, Current therapeutic research, clinical and experimental.
[13] J. Vester,et al. Endocrine and metabolic indices during administration of a lipophilic bis‐phenol, probucol , 1971, Clinical pharmacology and therapeutics.
[14] O. Brusco,et al. [Action of the new hypocholesteremic agent DH-581 (dithiobisphenol) in humans]. , 1971, Prensa medica argentina.
[15] D. Kritchevsky. Newer hypolipidemic agents. , 1971, Federation proceedings.
[16] D. Kritchevsky,et al. Influence of 4,4'-(Isopropylidenedithio)bis(2,6-di-t-butylphenol) (DH-581) on Experimental Atherosclerosis in Rabbits 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[17] J. W. Barnhart,et al. Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). , 1970, The American journal of clinical nutrition.
[18] R. Bradford,et al. The effect of [4,4'-(isopropylidenethio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjects. , 1969, Metabolism: clinical and experimental.
[19] B. Rifkind,et al. Lipid Lowering Drugs and Hyperlipidaemia , 2012, Drugs.
[20] P. Scott,et al. Lipid Lowering Drugs and Coronary Heart Disease , 2012, Drugs.
[21] J. W. Barnhart,et al. An overview of the biochemical pharmacology of probucol , 2006, Lipids.
[22] Nash Dt. Probucol, a new cholesterol lowering drug. , 1975 .
[23] T. Miettinen,et al. Treatment of severe and mild hypercholesterolaemia with probucol and neomycin. , 1975, Postgraduate medical journal.
[24] J. Sack,et al. Probucol in the long-term treatment of hypercholesterolaemia. , 1973, Current medical research and opinion.